Skip to main content

Table 3 EGFR point mutations

From: Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients

# Sex Ethnicity Smoking Status Source Tissue Response1 Exon CDS Mutation Amino Acid Previously Documented
44 F Asian N Pleura PR 20 G2549 > TT
C2691 > CT
S768I
L815L
[32–35]
none
11 F Asian Unk. Lung PR 20 G2566 > TT* V774L V774M [35, 36]
28 M Caucasian Y Brain SD 20 G2581 > AG G779S G779F [36]
35 F Caucasian Unk. Brain SD 20 G2703 > GA V819V [37]
47 F Asian N Lung SD 21 T2573 > GG L858R [5-7, 13, 15, 35, 38, 39]
  1. Point mutations detected in EGFR exons 20 and 21. All samples were classified as adenocarcinoma based on histology. Point mutations altering V774 and G779 have been previously documented to result in amino acid substitutions different than those found in this study.
  2. * = no mutations detected in normal tissue remaining after microdissection
  3. 1 = response as measured radiographically and defined by SWOG modification of the WHO criteria [20].
  4. PD = progressive disease, SD = stable disease, PR = partial response, Unk. = Unknown